Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2017
At a glance
- Drugs LU AF-35700 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms debut
- Sponsors Lundbeck A/S
- 06 Jul 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 06 Jul 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 15 Mar 2016 New trial record